Nature Communications · 2019 · 166 citations · 44 references
Life SciencesMolecular BiologyOncologyGene ExpressionMolecular OncologySignal TransductionCancer MetabolismCholesterol BiosynthesisCholesterol MetabolismMetabolic ReprogrammingMetabolic Reprogramming In CancerNuclear Receptor SignalingActivator ProteinsCellular Cholesterol HomeostasisCholesterol Biosynthesis ControlCholesterol-lowering EffectsHistone AcetylationPharmacological Inhibition Of Cholesterol BiosynthesisRor Nuclear ReceptorsTriple-negative Breast Cancer Therapy
Tumor subtype-specific metabolic reprogrammers could serve as targets of therapeutic intervention. Here we show that triple-negative breast cancer (TNBC) exhibits a hyper-activated cholesterol-biosynthesis program that is strongly linked to nuclear receptor RORγ, compared to estrogen receptor-positive breast cancer. Genetic and pharmacological inhibition of RORγ reduces tumor cholesterol content and synthesis rate while preserving host cholesterol homeostasis. We demonstrate that RORγ functions as an essential activator of the entire cholesterol-biosynthesis program, dominating SREBP2 via its binding to cholesterol-biosynthesis genes and its facilitation of the recruitment of SREBP2. RORγ inhibition disrupts its association with SREBP2 and reduces chromatin acetylation at cholesterol-biosynthesis gene loci. RORγ antagonists cause tumor regression in patient-derived xenografts and immune-intact models. Their combination with cholesterol-lowering statins elicits superior anti-tumor synergy selectively in TNBC. Together, our study uncovers a master regulator of the cholesterol-biosynthesis program and an attractive target for TNBC.
44
Fast and accurate short read alignment with Burrows–Wheeler transform
Heng Li, Richard Durbin · Bioinformatics · 2009 · 62.8K citations · Full text
IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis
Seth B. Coffelt, Kelly Kersten, Chris W. Doornebal et al. · Nature · 2015 · 1.7K citations · Full text
Medicine, Immunology, Oncology +14